Scott Gottlieb
American physician and investor.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner he was a clinical assistant professor at New York University School of Medicine, the FDA Deputy Commissioner for Medical and Scientific Affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, and a senior official at the Centers for Medicare and Medicaid Services. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.
Visit website: http://www.scottgottlieb.com/
See also: Food and Drug Administration (FDA) - Ensuring safety of drugs, medical supplies and food which is used daily.
Details last updated 13-Dec-2019
Scott Gottlieb News
35 reported cases of seizures following e-cigarette use
Independent - 03-Apr-2019
FDA stresses it is not clear whether e-cigarettes have triggered seizures in dozens of users
Read more...Ambrosia ceases young blood plasma treatment
CNN - 19-Feb-2019
Only 2 months after starting. Calling it a medical treatment may be contravened FDA guidance.
Read more...Drug approved as alternative method to CRISPR
Singularity Hub - 21-Aug-2018
Patisiran is a new drug capable of silencing genes based on RNA interference technology
Read more...FDA Target Rogue Gene Therapy Clinics
New York Times - 16-Nov-2017
FDA issued new guidelines for expedited review of stem cell and gene therapies. Will crack down ...
Read more...FDA Cracks Down on Stem Cell Clinics
New York Times - 28-Aug-2017
The F.D.A. reported actions against two large stem cell clinics and a biotech company calling th...
Read more...